CD86 and head and neck cancer: During early stages of head and neck cancer, tumor associated neutrophils develop an antigen-presenting phenotype (CD80+ CD86+ PDL-1-) and stimulate an anti-tumoral T-cell response, whereas in a more advanced tumor stage this phenotype expresses PDL-1 and thus has an immunosuppressing effect and thereupon promotes tumor progression44.